AventaMed DAC

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, AventaMed DAC sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

AventaMed DAC: 1 sponsored US clinical trial, 1 recruiting.

AventaMed DAC sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Ear Infection, with 1 trials.

Mid-pack sponsor footprint

AventaMed DAC is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

In-Office Clinical Study of the Solo+ TTD

NCT05741333

Therapeutic Areas

Ear Infection 1
Otitis Media 1

What is open in the AventaMed DAC pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Ear Infection (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

AventaMed DAC: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

AventaMed DAC sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share AventaMed DAC1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
AventaMed DAC sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

AventaMed DAC sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this AventaMed DAC page

1 registered trials is a research-attention snapshot, not an endorsement of AventaMed DAC or any single study.

  • 1 of AventaMed DAC's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Ear Infection is the condition AventaMed DAC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ear Infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

AventaMed DAC pipeline card: 1 registered trials from official public datasets.Report a data error.